HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic treatment with ethyl pyruvate attenuates the severity of liver injury in rats with severe acute pancreatitis.

AbstractOBJECTIVE:
The objective of the study was to evaluate the effect of ethyl pyruvate (EP) in ameliorating liver injury in rats with severe acute pancreatitis (SAP) and its possible mechanism.
METHODS:
Rats were randomly divided into control group, SAP group, and EP-treated group. Then, the tissue specimens were harvested for morphological studies, immunohistochemistry examination, reverse transcriptase-polymerase chain reaction, and Western blot analysis. The DNA-binding activity of nuclear factor κB was measured by electrophoretic mobility shift assay. The concentrations of serum amylase, alanine aminotransferase, and pancreatic tissue malondialdehyde and the activity of myeloperoxidase in the liver were determined.
RESULTS:
Treatment with EP after SAP was associated with a reduction in the severity of SAP and liver injury. Treatment with EP significantly decreased the hepatic mRNA expression of tumor necrosis factor α and interleukin 1β and ameliorated the activity of myeloperoxidase in the liver in SAP rats. Compared with the SAP group, treatment with EP significantly decreased the infiltration of inflammatory cells and markedly inhibited hepatic nuclear factor κB DNA binding; EP therapy dramatically inhibited high-mobility group box 1 expression from inflamed hepatic tissue.
CONCLUSIONS:
Our results demonstrate that EP might play a therapeutic role in liver inflammation in this SAP model, and these beneficial effects of EP are because of the modulation of high-mobility group box 1 and other inflammatory cytokine responses.
AuthorsZheng-Gang Luan, Hao Zhang, Xiao-Chun Ma, Cheng Zhang, Ren-Xuan Guo
JournalPancreas (Pancreas) Vol. 41 Issue 5 Pg. 729-37 (Jul 2012) ISSN: 1536-4828 [Electronic] United States
PMID22699144 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • HMGB1 Protein
  • Interleukin-1
  • NF-kappa B
  • Pyruvates
  • Tumor Necrosis Factor-alpha
  • ethyl pyruvate
  • Malondialdehyde
  • Taurocholic Acid
  • Peroxidase
Topics
  • Acute Disease
  • Animals
  • Blotting, Western
  • Gene Expression (drug effects)
  • HMGB1 Protein (metabolism)
  • Immunohistochemistry
  • Interleukin-1 (genetics)
  • Liver (drug effects, metabolism, pathology)
  • Liver Diseases (complications, drug therapy)
  • Male
  • Malondialdehyde (metabolism)
  • NF-kappa B (metabolism)
  • Pancreas (drug effects, metabolism, pathology)
  • Pancreatitis (chemically induced, complications, drug therapy)
  • Peroxidase (metabolism)
  • Pyruvates (pharmacology)
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Reverse Transcriptase Polymerase Chain Reaction
  • Severity of Illness Index
  • Taurocholic Acid
  • Tumor Necrosis Factor-alpha (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: